JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Search

Danaher Corp

Fermé

SecteurSoins de santé

174.62 0.32

Résumé

Variation du prix de l'action

24h

Actuel

Min

173.22

Max

176.42

Chiffres clés

By Trading Economics

Revenu

-168M

1B

Ventes

-887M

6B

P/E

Moyenne du Secteur

34.936

67.147

BPA

2.06

Rendement du dividende

0.77

Marge bénéficiaire

17.291

Employés

58,000

EBITDA

-514M

1.5B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+34.3% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.77%

2.36%

Prochains Résultats

21 juil. 2026

Date du Prochain Dividende

24 juil. 2026

Date du Prochain Détachement de Dividende

26 juin 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-11B

128B

Ouverture précédente

174.3

Clôture précédente

174.62

Sentiment de l'Actualité

By Acuity

23%

77%

76 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Danaher Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 avr. 2026, 11:36 UTC

Résultats

Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains -- Update

21 avr. 2026, 11:00 UTC

Résultats

Danaher Raises Adjusted Earnings Guidance, 1Q Revenue, Profit Rise

21 avr. 2026, 10:06 UTC

Résultats

Danaher 1Q Adjsuted Core Revenue Rose 0.5% >DHR

21 avr. 2026, 10:05 UTC

Résultats

Danaher Sees 2Q Adjsuted Core Revenue Up Low-Single Digits >DHR

21 avr. 2026, 10:05 UTC

Résultats

Danaher Still Sees 2026 Adjsuted Core Revenue Up 3%-6% >DHR

21 avr. 2026, 10:05 UTC

Résultats

Danaher Had Seen 2026 Adjusted EPS $8.35-$8.50 >DHR

21 avr. 2026, 10:04 UTC

Résultats

Danaher Raises 2026 View To Adj EPS $8.35-Adj EPS $8.55 >DHR

21 avr. 2026, 10:04 UTC

Résultats

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

21 avr. 2026, 10:00 UTC

Résultats

Danaher 1Q Cont Ops EPS $1.45 >DHR

21 avr. 2026, 10:00 UTC

Résultats

Danaher 1Q Adj EPS $2.06 >DHR

21 avr. 2026, 10:00 UTC

Résultats

Danaher 1Q Sales $5.95B >DHR

21 avr. 2026, 10:00 UTC

Résultats

Danaher 1Q EPS $1.45 >DHR

21 avr. 2026, 10:00 UTC

Résultats

Danaher 1Q Net $1.03B >DHR

17 avr. 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 avr. 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 févr. 2026, 20:06 UTC

Acquisitions, Fusions, Rachats

This Medical-Devices Stock Is Soaring. Danaher Is Buying the Company. -- Barrons.com

17 févr. 2026, 15:14 UTC

Acquisitions, Fusions, Rachats

Masimo Stock on Pace for Record Gains After Danaher Strikes Deal -- WSJ

17 févr. 2026, 14:39 UTC

Acquisitions, Fusions, Rachats

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17 févr. 2026, 13:30 UTC

Acquisitions, Fusions, Rachats

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17 févr. 2026, 13:15 UTC

Acquisitions, Fusions, Rachats

Danaher Strikes $10 Billion Deal for Masimo -- Update

17 févr. 2026, 13:03 UTC

Acquisitions, Fusions, Rachats

Danaher To Fund Masimo Acquisition With Cash on Hand, Debt Financing >DHR

17 févr. 2026, 13:03 UTC

Acquisitions, Fusions, Rachats

Danaher Sees More Than $125M Annual Cost Synergies, More Than $50M Annual Revenue Synergies by Fifth Full Year >DHR MASI

17 févr. 2026, 13:02 UTC

Acquisitions, Fusions, Rachats

Danaher Sees Masimo Deal Adding About 70c to Adjusted EPS in Fifth Full Year >DHR MASI

17 févr. 2026, 13:02 UTC

Acquisitions, Fusions, Rachats

Danaher Sees Masimo Deal Adding 15c-20c to Adjusted EPS in First Full Year >DHR MASI

17 févr. 2026, 13:02 UTC

Acquisitions, Fusions, Rachats

Masimo To Be Acquired By Danaher For $180.00 Per Share >MASI DHR

17 févr. 2026, 13:01 UTC

Acquisitions, Fusions, Rachats

Danaher to Buy Masimo for Total Enterprise Value of About $9.9 Billion >DHR MASI

17 févr. 2026, 13:00 UTC

Acquisitions, Fusions, Rachats

Danaher to Buy Masimo for $180/Share >DHR MASI

17 févr. 2026, 13:00 UTC

Acquisitions, Fusions, Rachats

Danaher To Acquire Masimo Corporation >DHR MASI

17 févr. 2026, 11:09 UTC

Acquisitions, Fusions, Rachats

Danaher Strikes $10 Billion Deal for Masimo -- WSJ

17 févr. 2026, 11:09 UTC

Acquisitions, Fusions, Rachats

Danaher Acquisition of Masimo Set to Be Announced Tuesday, Sources Say -- WSJ

Comparaison

Variation de prix

Danaher Corp prévision

Objectif de Prix

By TipRanks

34.3% hausse

Prévisions sur 12 Mois

Moyen 233.74 USD  34.3%

Haut 270 USD

Bas 184.04 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

16 ratings

14

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

189.8851 / 196.5Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

76 / 347Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat